The therapy works by harvesting a patient’s own T cells and engineering them to express a synthetic receptor that recognizes CD19, a surface protein found on B cells. Nearly all approved CD19 CAR-T products use a binding domain derived from the FMC63 antibody, which recognizes an epitope encoded by exons 3 and 4 of the CD19 gene. When cancer cells lose or alter the CD19 antigen, the engineered T cells have nothing to latch onto, and the malignancy escapes immune destruction. Previous work has shown that a splice variant called CD19Δexon2, in which exon 2 is skipped during RNA processing, is linked to therapy resistance and relapse. What has been missing is a reliable way to identify, before treatment ever begins, which patients carry this risk.

The research team, led by Søren Helweg Dam, Giorgia Moranzoni and Lars Rønn Olsen of the University of Copenhagen, together with colleagues at the Technical University of Denmark, Rigshospitalet and Odense University Hospital, took a computational approach. They mined publicly available RNA-sequencing data from four B-ALL patients treated with CD19 CAR-T therapy—one complete responder, one non-responder, and two who relapsed after an initial response. For each patient, they quantified the percent spliced in (PSI) of CD19 exon 2, a metric that estimates how much of the CD19 messenger RNA retains exon 2 versus skipping it. A lower PSI means a higher abundance of the CD19Δexon2 variant.

The pattern was striking. The patient who relapsed earliest—just 1.5 months after infusion—had the lowest pre-treatment exon 2 PSI, with 21 RNA reads spanning the exon 1–3 junction, a direct signature of exon 2 skipping. The non-responder showed 13 such reads, the slow relapser only one, and the complete responder none at all. After treatment, CD19 read coverage dropped sharply in all patients who initially responded, consistent with effective B-cell depletion, while the non-responder retained substantial CD19 expression and continued exon 1–3 junction usage. Although the cohort is far too small for statistical inference, the qualitative concordance between exon 2 inclusion and clinical outcome suggests that reduced exon 2 retention may be associated with CAR-T therapy failure.

To understand why skipping exon 2 might undermine the therapy, the researchers turned to structural modeling. They retrieved the experimentally resolved structure of canonical CD19 from the AlphaFold Database and predicted the structure of the Δexon2 variant de novo using AlphaFold3. In the canonical protein, the two discontinuous segments of the FMC63 epitope fold into close spatial proximity, forming a contiguous binding surface. Exon 2 skipping disrupts this arrangement, separating the epitope elements and likely impairing antibody accessibility. The finding provides a plausible mechanistic explanation for the experimentally observed reduction in FMC63 binding affinity to the variant protein, positioning exon 2 as a stabilizing element of the functional epitope.

Experimental studies add weight to this model. CD19 isoforms lacking exon 2 exhibit defective folding, abnormal glycosylation, and impaired interaction with the CD81 chaperone complex, causing the misfolded protein to be retained in the endoplasmic reticulum rather than trafficked to the cell surface. Only a small fraction of the variant escapes quality control and reaches the membrane, and that population appears unstable and poorly recognized by CD19-directed antibodies. Reduced CAR recognition of CD19Δexon2 therefore arises from both impaired trafficking and altered surface conformation, leading to markedly diminished antigen density.

Perhaps the most provocative finding is that exon 2 skipping is not exclusively a therapy-induced phenomenon. The team analyzed larger RNA-sequencing datasets from treatment-naïve B-ALL (75 samples from the iCOPE/STAGING study), newly diagnosed DLBCL (553 samples from the GOYA trial), and healthy tissues from the GTEx project (1,048 blood and 255 spleen samples). Exon 2 inclusion was uniformly high in B-ALL and healthy tissues, with median PSI values of 96.3 percent, 96.9 percent and 97.7 percent respectively, and roughly 96 to 97 percent of samples in these groups showed near-complete exon retention. DLBCL, by contrast, displayed marked heterogeneity: the median PSI was 91.6 percent, only 59.5 percent of samples met the 90 percent inclusion threshold, and 86.8 percent showed measurable skipping, including one patient with a PSI as low as 22.8 percent.

These results suggest that CD19Δexon2 is a naturally occurring, low-frequency splice variant present in both malignant and normal B cells, rather than a strictly disease-specific or therapy-induced transcript. Under the selective pressure of CD19-directed CAR-T therapy, malignant cells already expressing the variant may gain a survival advantage and expand, producing the apparent enrichment of the isoform in relapsed disease. This reframes the biology: the variant is not created by the treatment but unmasked by it, which is precisely what makes pre-treatment detection potentially valuable.

The translational implications are considerable. Because bulk RNA sequencing of leukemic cells is increasingly performed as part of the diagnostic workup for B-ALL, exon 2 PSI could be computed as an additional feature at no extra experimental cost. Alternatively, quantitative PCR assays targeting the exon 1–3 junction could provide a rapid and inexpensive test to stratify relapse risk or monitor splicing changes during follow-up. The epitope connection may extend even further: the parental antibody of blinatumomab, a bispecific T-cell engager now moving into front-line B-ALL therapy, competes with FMC63 for CD19 binding, suggesting that structural disruption caused by exon 2 skipping could also compromise blinatumomab-mediated cytotoxicity—though this remains to be formally tested.

The authors are careful to emphasize the limitations. The CAR-T cohort contains only four patients, precluding statistical analysis and any claim of causality or predictive value. Post-treatment samples had sparse read coverage, bulk RNA-seq cannot resolve whether the variant is co-expressed with canonical CD19 in the same cells or confined to distinct subclones, and pre-treatment tumor burden may confound PSI measurements, since normal B cells express predominantly canonical CD19. Protein-level consequences remain to be verified experimentally, and the structural analyses rely on computational modeling. Still, the consistency between structural predictions, patient-level RNA patterns and baseline tissue distributions strengthens the biological plausibility of the findings, and larger prospective studies using targeted long-read sequencing or isoform-specific qPCR could determine whether CD19 exon 2 skipping is merely a correlate of poor response or a functional determinant of resistance. Either outcome would sharpen the understanding of CD19 biology and help clinicians decide which patients might benefit most from multi-target CAR strategies directed against CD19 together with CD20 or CD22.

Subject of Research: CD19 exon 2 alternative splicing as a potential prognostic biomarker for relapse after anti-CD19 CAR-T cell therapy in B-cell malignancies

Article Title: CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse

Article References: Dam, S. H., Moranzoni, G., Høie, M. H., Modvig, S., Wadt, K. A. W., Als-Nielsen, B., Schmiegelow, K., Vitting-Seerup, K., Barnkob, M. B., & Olsen, L. R. (2026). CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse. Frontiers in Molecular Medicine, 6, Article 1763390. https://doi.org/10.3389/fmmed.2026.1763390

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1763390

Keywords: CAR-T therapy, CD19, alternative splicing, exon 2 skipping, B-cell acute lymphoblastic leukemia, DLBCL, relapse, biomarker, antigen escape, FMC63 epitope, RNA sequencing, immunotherapy resistance

The most intensively explored strategy for overcoming relapse is multi-antigen targeting. When tumours are pushed by a single-target CAR, they frequently survive by losing, downregulating or masking the targeted antigen, a phenomenon well documented after CD19-directed therapy. Three architectural solutions dominate current development. Pooled approaches administer two independently manufactured monospecific products, such as separate CD19- and CD22-directed cells, preserving modular design flexibility but risking dominance of one population after infusion. Bicistronic dual-CAR T cells carry two independent receptors within the same cell, creating an OR-gate in which either antigen triggers cytotoxicity, providing more uniform cell-by-cell coverage at the cost of a larger genetic payload and more complex signalling. Tandem CARs fuse two binding domains into a single receptor chain, ensuring both specificities on every engineered cell, but their performance is acutely sensitive to structural configuration, including domain order, linker flexibility, hinge length and binder affinity, and steric hindrance can compromise recognition of single-antigen-positive cells. Clinical studies of CD19/CD22 and CD19/CD20 constructs have shown feasibility and antitumour activity in acute lymphoblastic leukaemia and large B-cell lymphoma, but no strategy has yet established universal superiority over optimised single-target products.

Understanding why requires a look at the receptor generations themselves. First-generation CARs coupled an antibody-derived single-chain variable fragment directly to the CD3ζ signalling domain and, lacking costimulation, persisted poorly in patients. Second-generation constructs added a single costimulatory domain such as CD28 or 4-1BB, dramatically improving expansion, persistence and resistance to exhaustion, and they remain the clinical standard underlying every approved therapy. Third-generation receptors combining two costimulatory domains have shown stronger preclinical activity but no consistent clinical advantage, and may amplify inflammatory toxicity. Fourth-generation armoured CARs add inducible transgenes encoding cytokines such as IL-12 or IL-18 that remodel the immunosuppressive tumour microenvironment and recruit endogenous immune cells, an approach considered particularly attractive for solid tumours, though controlling transgene expression and avoiding cytokine-mediated toxicity remain significant barriers to translation.

Solid tumours remain the field’s hardest problem, and clinical trials have delivered sobering lessons. A landmark Phase I trial of EGFRvIII-directed CAR T cells in glioblastoma showed that engineered cells successfully trafficked to tumour sites yet produced no durable responses; post-treatment analyses revealed rapid loss of the target antigen alongside increased regulatory T cells, tumour-associated macrophages and PD-L1 expression, a textbook demonstration of adaptive immune resistance. An earlier HER2-directed trial suffered a fatal on-target, off-tumour pulmonary toxicity caused by low-level HER2 expression in normal lung, an event that reshaped the entire discipline’s approach to antigen selection and dose escalation. Mesothelin-directed cells have been safe in mesothelioma, pancreatic and ovarian cancers but have mostly achieved disease stabilisation rather than regression. The recurring barriers are heterogeneous antigen expression, dense desmoplastic stroma that physically blocks infiltration, abnormal vasculature, and a microenvironment saturated with TGF-β, IL-10, adenosine, regulatory T cells and myeloid-derived suppressor cells, all of which drive CAR-T-cell exhaustion through inhibitory receptors such as PD-1, TIM-3 and LAG-3.

Against this backdrop, a genuine milestone has now been reached. Satri-cel, a CAR targeting claudin 18 isoform 2, a tight-junction protein exposed on gastric cancer cells but largely concealed in healthy mucosa, significantly prolonged median progression-free survival from 1.77 to 3.25 months compared with physician’s-choice treatment in the randomised Phase II CT041-ST-01 trial in heavily pretreated gastric and gastro-oesophageal junction cancer. In June 2026, China’s National Medical Products Administration approved the product for CLDN18.2-positive, HER2-negative advanced gastric cancer after at least two prior systemic lines, making it the first regulator-approved CAR-T-cell therapy anywhere in the world indicated specifically for a solid tumour. The review’s authors are careful to frame this as proof of principle rather than a universal solution: responses still depend on antigen density and heterogeneity, grade 3 or worse adverse events were frequent, and the treatment demands lymphodepletion and specialist monitoring.

Toxicity management is simultaneously becoming more sophisticated and more predictive. Cytokine release syndrome, driven largely by IL-1 and IL-6 from activated macrophages, remains the most common acute complication and is treated first-line with tocilizumab, with corticosteroids reserved for severe cases because excessive immunosuppression may erode CAR-T-cell persistence. Immune effector cell-associated neurotoxicity syndrome, linked to endothelial activation and blood-brain barrier disruption, can progress from encephalopathy to cerebral oedema, and severe CRS can also trigger coagulopathy and prolonged cytopenias. The review highlights an emerging biomarker toolkit that goes well beyond IL-6: persistently elevated ferritin and C-reactive protein track with severe CRS, soluble IL-2 receptor alpha adds independent predictive value as a T-cell activation marker, and endothelial injury markers including angiopoietin-2, von Willebrand factor and D-dimer illuminate the vascular dimension of toxicity. Machine-learning models, particularly gradient-boosting algorithms applied to multiparametric datasets, have shown encouraging accuracy in flagging patients destined for severe ICANS or high-grade CRS before clinical deterioration begins.

Cost and accessibility constitute what may ultimately be the field’s defining constraint. Approved autologous CAR-T products routinely cost between 400,000 and 500,000 US dollars per patient once manufacturing, hospitalisation, lymphodepletion and toxicity management are counted, and the individualised production workflow, from leukapheresis through genetic modification, expansion, quality control and cryopreserved transport, typically takes two to four weeks during which rapidly progressive disease may render a patient ineligible. Allogeneic off-the-shelf products manufactured from healthy donors, enabled by CRISPR/Cas9 disruption of the endogenous T-cell receptor and HLA molecules to prevent graft-versus-host disease and rejection, promise immediate availability and economies of scale. Early candidates such as ALLO-501 and its successor ALLO-501A, which adds CD52 disruption permitting selective lymphodepletion, produced clinically meaningful responses in lymphoma with no reported graft-versus-host disease, though host rejection, limited persistence and small early-phase datasets keep their advantage over autologous products unproven. Automated closed-system manufacturing, non-viral transposon-based gene transfer, point-of-care production and rational combinations with checkpoint inhibitors or targeted agents such as BTK and BCL-2 inhibitors are all being pursued to compress costs further.

Alternative cellular platforms are broadening the engineering arsenal in parallel. γδ T cells, which recognise stressed and transformed cells independently of MHC presentation and carry a naturally low risk of graft-versus-host disease, offer a compelling route around antigen escape, but they constitute only 1 to 5 percent of circulating lymphocytes, their ex vivo expansion is highly donor-dependent, subset heterogeneity complicates manufacturing, and their in vivo persistence falls short of conventional αβ CAR-T cells. CAR-NK cells share the off-the-shelf appeal and a favourable safety profile, with early CD19-directed trials showing encouraging responses, but genetic modification remains inefficient and persistence is limited. More exotic platforms, including CAR macrophages that phagocytose tumour cells and remodel stroma, CAR neutrophils capable of penetrating glioblastoma, invariant NKT cells, double-negative T cells, MAIT cells and fibroblast activation protein-targeted cells that attack cancer-associated fibroblasts, all show preclinical promise but face unresolved questions of scalability, persistence and long-term safety. Switchable CAR systems that decouple recognition from activation through soluble adaptor molecules add a further layer of control, allowing clinicians to withdraw activity in the event of severe toxicity or retarget cells to new antigens without manufacturing new products.

The review’s synthesis is deliberately unsentimental. CAR-T-cell therapy is a major advance, not a universally effective cancer treatment, and its next decade will be judged on dimensions that extend far beyond antitumour potency: safer multi-target and logic-gated constructs, validated biomarker panels integrated with artificial intelligence for toxicity prediction and patient selection, automated and decentralised manufacturing, rigorous randomised evidence for allogeneic and alternative platforms, and health-economic and regulatory frameworks capable of delivering these therapies beyond specialised centres in high-income countries. The approval of the first solid-tumour CAR-T product demonstrates that rational antigen selection can crack previously resistant cancers; sustaining that momentum across tumour types, and making the treatments affordable and equitable, is now the central scientific and societal challenge.

Subject of Research: Future directions of chimeric antigen receptor T-cell therapy, including multi-target designs, solid tumour challenges, toxicity biomarkers and cost reduction strategies

Article Title: The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment

Article References: The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment. (n.d.). https://doi.org/10.3389/fmmed.2026.1931159

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1931159

Keywords: CAR-T cell therapy, immunotherapy, solid tumours, antigen escape, cytokine release syndrome, allogeneic CAR-T, γδ T cells, biomarkers, manufacturing costs, claudin 18.2, CAR-NK cells, genome editing

CD19 has become the single most important target in B-cell malignancy therapy. Chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates overwhelmingly depend on the dense, consistent expression of CD19 on the surface of malignant B lymphocytes. Yet relapse after CD19-directed immunotherapy is common, and one of the best-documented mechanisms of that relapse is the loss or masking of surface CD19. Tumor cells that downregulate the antigen effectively become invisible to the therapy, resuming their growth once the immune pressure has been evaded. Understanding what controls CD19 abundance at the cell surface, and how clinical drugs might stabilize it, is therefore a question of substantial therapeutic consequence. The new work addresses that question directly, and its answer involves an unlikely player.

Matriptase, encoded by the ST14 gene, is a type II transmembrane serine protease with a well-established role in epithelial biology. It is best known for initiating proteolytic cascades that regulate barrier function, filaggrin processing, and growth factor signaling in skin and other epithelial tissues. Its dysregulation has been implicated in epithelial cancers, where excessive matriptase activity can promote invasion and metastasis. Its role in lymphoid malignancies, by contrast, has been far less explored. The new study now places matriptase at the center of a drug-responsive circuit in malignant B cells, where it appears to act on the fate of CD19 itself, preserving the antigen in its extracellular, antibody-accessible form rather than allowing it to be shed, internalized, or otherwise lost from the cell surface.

The central observation is a causal chain. When malignant B cells are exposed to ibrutinib, the drug does more than inhibit BTK signaling; it triggers an increase in matriptase activity or abundance. That protease, in turn, acts to maintain extracellular CD19. In practical terms, cells treated with the drug retain the surface target that CAR-T cells and CD19-directed antibodies recognize, whereas cells in which the matriptase arm of this circuit is disrupted lose that protection and become prone to antigen escape. The authors frame this as a mechanism by which ibrutinib limits antigen escape in B-cell malignancy, a framing that carries immediate translational weight because ibrutinib is already approved and widely used in chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell disorders.

The clinical logic of the finding is compelling. Ibrutinib and CD19-directed immunotherapies are frequently considered in overlapping patient populations, and sequencing decisions between BTK inhibition and cellular immunotherapy are often made empirically. If ibrutinib treatment stabilizes surface CD19, then a period of BTK inhibition before leukapheresis or CAR-T infusion could, in principle, improve the quality of the target presented to the engineered cells, reducing the likelihood that the manufactured product encounters antigen-low tumor cells. Conversely, the study raises a caution: interventions or tumor adaptations that suppress matriptase might undermine CD19 display and thereby predispose patients to escape from CD19-directed therapies, even when the malignant cells remain otherwise sensitive to cytotoxic pressure.

Antigen escape is not a single mechanism but a family of them. Tumor cells can mutate the CD19 locus, introduce truncating mutations, alter exon splicing so that the epitope is lost while the protein remains, internalize the antigen faster than it is replaced, or shield it from antibody binding through changes in the membrane microenvironment. Each of these routes has been documented in patients relapsing after CD19 CAR-T therapy. What the new study contributes is the idea that the extracellular maintenance of CD19 is an actively regulated process, one that a protease can influence and that an approved drug can modulate. That reframing matters because it converts antigen loss from an apparently random escape event into a process with identifiable molecular control points that might be monitored and manipulated.

The mechanistic details also connect two previously separate strands of B-cell biology. BTK signaling sits at the heart of the B-cell receptor pathway, and its chronic engagement is a hallmark of many B-cell malignancies, particularly those dependent on active B-cell receptor signaling such as chronic lymphocytic leukemia and mantle cell lymphoma. Ibrutinib’s inhibition of BTK disrupts survival signals and drives malignant cells toward apoptosis. The new data suggest that this well-characterized pharmacologic action has a second, previously underappreciated consequence: a protease-mediated remodeling of the tumor cell surface that favors target retention. In effect, a drug designed to weaken the tumor may simultaneously make the tumor easier to see for the immune system, an unintended benefit that could be exploited deliberately.

For researchers in the immunotherapy field, the study suggests several lines of immediate follow-up. Measuring matriptase activity in patient samples before CD19-directed therapy could reveal whether protease status predicts who is at risk of antigen-negative relapse. Pharmacologic or genetic modulation of matriptase in preclinical models could test whether enhancing its activity further improves CD19 persistence under immune pressure. Combination trials pairing ibrutinib with CD19 CAR-T or bispecific antibodies are already underway for various indications, and the new mechanism provides a biological rationale for such combinations that goes beyond simple additive cytotoxicity. Biomarker strategies that track surface CD19 density longitudinally during BTK inhibition could also help clinicians time cellular therapy infusions for maximal target availability.

There are, of course, important caveats. Matriptase is a protease with pleiotropic effects, and its activity in epithelial cancers has often been associated with tumor progression, so any therapeutic strategy aimed at boosting its function in lymphoid malignancy would need to account for tissue-specific context and potential off-tumor consequences. The relationship between ibrutinib exposure, matriptase activation, and CD19 maintenance will also need to be validated across the full diversity of B-cell malignancies, since the biology of chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma differ substantially in their dependence on BTK signaling and their patterns of antigen expression. Clinical outcomes, not only cell-culture measurements, will ultimately determine whether the mechanism translates into lower rates of antigen-escape relapse in treated patients.

Even with those qualifications, the study adds a genuinely new concept to the immunotherapy conversation: that the target itself can be pharmacologically defended. Much of the effort in overcoming antigen escape has focused on the therapeutic side, through multi-antigen CAR constructs targeting CD19 together with CD20 or CD22, or through sequential and dual-targeting strategies. The alternative approach suggested here is to act on the tumor cell so that it continues to display the antigen the therapy needs. If ibrutinib-triggered matriptase activity proves to be a reliable and safe lever for maintaining extracellular CD19, it would represent a rare example of an approved small-molecule drug being repurposed, at least conceptually, as a target-preservation agent for cellular immunotherapy. In a field where antigen loss remains one of the leading causes of treatment failure, that is an idea with the potential to reshape how BTK inhibitors and CD19-directed therapies are sequenced and combined in the clinic.

Subject of Research: Ibrutinib-triggered matriptase activity maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article Title: Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article References: Lu, X.-J., Lai, H.-F., Hung, Y.-S., Wang, Y.-J., Wu, S.-C., Wang, J.-K., Wu, Y.-Y., & Chiu, Y.-L. (2026). Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03306-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03306-5

Keywords: ibrutinib, matriptase, CD19, antigen escape, B-cell malignancy, BTK inhibitor, CAR-T therapy, immunotherapy, Cell Death Discovery, serine protease, chronic lymphocytic leukemia, target preservation